EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Treatment of Youth‐Onset Type 2 Diabetes: Focus on SGLT‐2 Inhibitor Use

Silva Arslanian iD, Timothy Barrett iD, Naim Shehadeh iD

Pediatric Diabetes · 2026-01 · 2026 (1)

DOI: 10.1155/pedi/4555805 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pediatric Diabetes, online erschienen am 01.04.2026. Verfasst von Silva Arslanian und 2 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA, pitt.edu. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The upward trajectory of childhood and adolescent type 2 diabetes (T2D; youth‐onset T2D) is a global health issue, disproportionately affecting non‐white, ethnically diverse, and socioeconomically disadvantaged subgroups. Youth‐onset T2D displays a more aggressive phenotype, with faster disease progression and earlier onset of severe complications when compared to adult‐onset T2D. Despite this, the therapeutic options for the management of youth‐onset T2D have historically been limited. Over the last few years, multiple new therapies across a range of drug classes, including glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium–glucose cotransporter‐2 (SGLT‐2) inhibitors, have been approved for use in youth‐onset T2D. Despite this, patient recruitment to pediatric and adolescent trials remains a major challenge in youth‐onset T2D, and there is currently a lack of large‐scale, long‐term clinical evidence for new treatment classes in this patient population. In this review, we provide an overview of the current treatment landscape in youth‐onset T2D and summarize the available clinical data for SGLT‐2 inhibitors in patients with youth‐onset T2D, based on a targeted literature search.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Hypoglycemic AgentsHumansAdolescentChildAge of Onset

Stichwörter der Autor:innen

adolescentschildhoodpediatricsodium–glucose co-transporter-2treatmenttype 2 diabetes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA, pitt.edu.
  • University of Birmingham, Birmingham, UK, birmingham.ac.uk.
  • Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel, biu.ac.il.

ORCID-Profile: Silva Arslanian, Timothy Barrett, Naim Shehadeh

Förderung

  • AstraZeneca

Zitieren

APA

Arslanian, S., Barrett, T., & Shehadeh, N. (2026). Treatment of Youth‐Onset Type 2 Diabetes: Focus on SGLT‐2 Inhibitor Use. Pediatric Diabetes, 2026(1). https://doi.org/10.1155/pedi/4555805

Vancouver

Arslanian S, Barrett T, Shehadeh N. Treatment of Youth‐Onset Type 2 Diabetes: Focus on SGLT‐2 Inhibitor Use. Pediatric Diabetes. 2026;2026(1). doi:10.1155/pedi/4555805

BibTeX
@article{Arslanian2026,
  author = {Arslanian, Silva and Barrett, Timothy and Shehadeh, Naim},
  title = {Treatment of Youth‐Onset Type 2 Diabetes: Focus on SGLT‐2 Inhibitor Use},
  journal = {Pediatric Diabetes},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/pedi/4555805}
}
Kostenlos starten →